Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors

Sucandy, Iswanto; Cheek, Susannah; Golas, Benjamin; Tsung, Allan; Geller, David A.; Marsh, J. Wallis

doi:10.1016/j.hpb.2016.06.010

Cited by 44 publications

(25 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the extent and severity of the disease, a range of therapies are used in the management of HCC such as surgical resection, liver transplantation, and loco regional therapies like radiofrequency ablation and transarterial chemoembolization. Indeed, 70–80% of patients are diagnosed when disease extent precludes radical treatment and can be treated only with palliative loco reginal therapies with poor prognosis, typically living for only 6–20 months after diagnosis . Despite comprehensive understanding of signaling pathways involved in HCC (e.g., Ras, STAT3, and AKT/mTOR), efficient molecularly targeted agents are limited due to the distinct complexity for HCC .…”

Section: Advanced Liver Diseasesmentioning

confidence: 99%

“…Indeed, sorafenib and lenvatinib, which are multityrosine kinase inhibitors, were the only approved systemic treatment confirmed to provide a limited increase in survival of 2–3 months. [19a,22] None of the molecular therapies tested clinically in last 5 years showed positive results after sorafenib progression except regorafenib, which nevertheless only provided slightly improved median survival of 2.8 months in HCC patients who tolerated sorafenib . Bypassing the challenge developing small molecule drugs for HCC, pharmaceutical researchers today turn to other therapeutic modalities such as RNA interference technology and cancer‐killing viruses .…”

Section: Advanced Liver Diseasesmentioning

confidence: 99%

“…Clinical studies demonstrated that patients with untreated colorectal liver metastasis have 31% survival rate at 1 year, 7.9% at 2 years, 2.6% at 3 years, and 0.9% at 4 years. [19a] The additional chemotherapy only improves median survival from 6–12 months to 20 months …”

Section: Advanced Liver Diseasesmentioning

confidence: 99%

See 2 more Smart Citations

Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver

Huang

2018

Adv Funct Materials

View full text Add to dashboard Cite

The liver contains intricate immunological mechanisms, capable of inducing both immune activation and suppression for the maintenance of a homeostatic immune environment. From an immunological point of view, chronic liver disease is indeed a result of the imbalance of pro-and anti-inflammatory responses. Therefore, application of immunotherapy in liver diseases is logical and contains a huge potential for future development. Despite rapid advances in immunotherapy, research at the interdisciplinary interface of immunology and material science is important for further enhancement of immunotherapeutic efficiency and reduction of side effects. Moreover, the liver is particularly suitable for the application of nanomaterial-based immunotherapy due to its biological filtration function to sequester a majority of administrated nanoparticles from systemic circulation. Here, an insight of advanced liver diseases and how liver cells exert their immune functions in the diseased liver is summarized first to provide basic principles for therapeutic application, followed by an overview of the latest studies on nanomaterial-based immunotherapy for liver diseases.

show abstract

Section: Advanced Liver Diseasesmentioning

confidence: 99%

Section: Advanced Liver Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver

Huang

2018

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…Minimally invasive, percutaneous ablation has become an integral part in modern treatment regimes of local and metastatic neoplastic diseases [1,2]. This is particularly true for the management of primary and secondary hepatic malignancies, for which local tumor ablation procedures are embedded in current guidelines [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

MR-guided microwave ablation in hepatic malignancies: clinical experiences from 50 procedures

Weiß

Winkelmann

Gohla

et al. 2020

International Journal of Hyperthermia

View full text Add to dashboard Cite

Purpose: To investigate technical success, technique efficacy, safety and outcome of MR-guided microwave ablation (MWA) in hepatic malignancies. Material and methods: In this prospective IRB-approved study, patients scheduled for percutaneous treatment of hepatic malignancies underwent MR-guided MWA in a closed-bore 1.5 T MR system. Technical success was assessed on post-procedural MR control imaging. Technique efficacy was evaluated 4 weeks after the procedure on multi-parametric MRI. Assessment of safety followed the Society of Interventional Radiology grading system. Kaplan-Meier survival estimates were calculated to evaluate overall survival (OS), time to local tumor progression (TLTP), and time to non-target progression (TNTP). Results: Between 2015 and 2019, 47 patients (60.5 ± 12.2 years; 39 male) underwent 50 procedures for 58 hepatic tumors (21 hepatocellular carcinomas; 37 metastases). Mean target tumor size was 16 ± 7mm (range: 6-39 mm). Technical success and technique efficacy were 100% and 98%, respectively. Lesions were treated using 2.6 applicator positions (range: 1-6). Mean energy, ablation duration per tumor, and procedure duration were 43.2 ± 23.5 kJ, 26.7 ± 13.1 min and 211.2 ± 68.7 min, respectively. 10 minor (20%) and 3 major (6%) complications were observed. Median post-interventional hospital admission was 1 day (range: 1-19 days). Median OS was 41.6 (IQR: 26.4-) months. Local recurrence occurred after 4 procedures (8%) with TLTP ranging between 3.1 and 41.9 months. Non-target recurrence was observed in 64% of patients after a median TNTP of 13.8 (IQR 2.3-) months. Conclusion: MR-guided MWA allows for safe and successful treatment of hepatic malignancies with a high technique efficacy however with relatively long procedure durations.

show abstract

“…3 The RFA has been widely applied in practice owing to the small trauma and few complications, with high inactivation rate of tumor and low relapse rate. 4,5 The RFA requires the guidance of ultrasound or computed tomography (CT) imaging to determine the location, number, and size of the tumor, whereas the angle of needle insertion, ablation range, and ablation effect should be also identified. 6,7 At present, assistant means, including conventional ultrasound, contrast-enhanced ultrasound (CEUS), three-dimensional ultrasound, 8,9 CT plain scan, contrast-enhanced computed tomography (CECT), and threedimensional CT have emerged.…”

Section: Introductionmentioning

confidence: 99%

The Application Comparison of Contrast-Enhanced Ultrasound and Contrast-Enhanced Computed Tomography in Radiofrequency Ablation Treatment for Hepatocellular Carcinoma

Liu

Wang

Xing

et al. 2019

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Objective: To compare the application value of contrast-enhanced ultrasound (CEUS) and contrast-enhanced computed tomography (CECT) in radiofrequency ablation (RFA) for treatment of hepatocellular carcinoma (HCC). Methods: A total of 112 patients with primary HCC were enrolled for the treatment of RFA and they were randomly equally divided into the CEUS group and CECT group. The gender, age, and number and maximum diameter of tumors between the two groups were compared. The median duration of follow-up was 27.0 months and the clinical outcomes were compared. Results: The average examination time period before ablation, of guiding needle insertion and of ablation in the CEUS group were significantly shorter than those in the CECT group ( p < 0.05). The complete ablation rate of the CEUS group was significantly higher than that of the CECT group (86.36% vs. 73.17%, v 2 = 4.618, p = 0.032). There was no comparative difference in the incidence of complications (including fever, infection, pain, and liver injury) between the two groups ( p > 0.05). The relapse rate of the CEUS group was lower and the survival rate was higher than that in the CECT group ( p < 0.05). Conclusions: Compared with the CECT, the RFA for treatment of HCC guided by the CEUS shorten the time of examination and treatment. The immediate postoperative assessment can improve the overall complete ablation rate, reduce the relapse rate, and increase the survival rate, which provides insights for the clinical application.

show abstract

Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors

Abstract: Background: We aim to investigate long-term survival outcomes in patients undergoing radiofrequency ablation (RFA), based on our longitudinal 5 and 10 year follow-up data.

Cited by 44 publications

References 27 publications

Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver

Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver

MR-guided microwave ablation in hepatic malignancies: clinical experiences from 50 procedures

The Application Comparison of Contrast-Enhanced Ultrasound and Contrast-Enhanced Computed Tomography in Radiofrequency Ablation Treatment for Hepatocellular Carcinoma

Contact Info

Product

Resources

About